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STUDY QUESTION:Which genes are confidently linked to human monogenic male infertility?
SUMMARY ANSWER: Our systematic literature search and clinical validity assessment reveals that a total of 78 genes are currently confi-
dently linked to 92 human male infertility phenotypes.
WHAT IS KNOWN ALREADY: The discovery of novel male infertility genes is rapidly accelerating with the availability of next-generating
sequencing methods, but the quality of evidence for gene–disease relationships varies greatly. In order to improve genetic research, diagnos-
tics and counseling, there is a need for an evidence-based overview of the currently known genes.
STUDY DESIGN, SIZE, DURATION: We performed a systematic literature search and evidence assessment for all publications in
Pubmed until December 2018 covering genetic causes of male infertility and/or defective male genitourinary development.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Two independent reviewers conducted the literature search and included
papers on the monogenic causes of human male infertility and excluded papers on genetic association or risk factors, karyotype anomalies
and/or copy number variations affecting multiple genes. Next, the quality and the extent of all evidence supporting selected genes was
weighed by a standardized scoring method and used to determine the clinical validity of each gene–disease relationship as expressed by the
following six categories: no evidence, limited, moderate, strong, definitive or unable to classify.
MAIN RESULTS AND THE ROLE OF CHANCE: From a total of 23 526 records, we included 1337 publications about monogenic
causes of male infertility leading to a list of 521 gene–disease relationships. The clinical validity of these gene–disease relationships varied
widely and ranged from definitive (n = 38) to strong (n = 22), moderate (n = 32), limited (n = 93) or no evidence (n = 160). A total of 176
gene–disease relationships could not be classified because our scoring method was not suitable.
LARGE SCALE DATA: Not applicable.
LIMITATIONS, REASONS FOR CAUTION: Our literature search was limited to Pubmed.
WIDER IMPLICATIONS OF THE FINDINGS: The comprehensive overview will aid researchers and clinicians in the field to establish
gene lists for diagnostic screening using validated gene–disease criteria and help to identify gaps in our knowledge of male infertility. For future
studies, the authors discuss the relevant and important international guidelines regarding research related to gene discovery and provide spe-
cific recommendations for the field of male infertility.
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Introduction
Infertility is defined as the inability to conceive within 1 year of unpro-
tected sexual intercourse (Zegers-Hochschild et al., 2009). Approxi-
mately 7% of the male population is affected, collectively explaining
infertility in half of all couples affected (Irvine, 1998; Winters and
Walsh, 2014; Krausz and Riera-Escamilla, 2018).
The etiology of infertility is highly heterogeneous, which is not sur-
prising when considering that both male and female reproductive sys-
tems need to function in a combined and precisely coordinated
fashion in order to conceive a child. Studies aiming to elucidate the
genetic basis of fertility defects in both human and mice have defined
numerous crucial pathways for male infertility, including sexual differ-
entiation, development of the genitourinary system and gametogenesis
(Jamsai and O’Bryan, 2011; Krausz and Riera-Escamilla, 2018).
Currently more than 600 male infertility genes have been described in
the Jackson Laboratory’s Mouse Genome Informatics database
(http://www.informatics.jax.org/) and 2300 testis-enriched genes are
currently known in human (Schultz et al., 2003). High-impact muta-
tions in any of these genes will always remain at very low frequency in
the population because of their impact on fitness. This means that in
order to find recurrently mutated genes and novel genes confidently
linked to infertility one has to screen large cohorts of patients for
pathogenic variants in large numbers of genes. This has been laborious
and expensive for a long time due to limitations of traditional genetic
assays such as Sanger sequencing. Since the first introduction of next-
generation sequencing (NGS) in 2005, the technology has evolved to
allow rapid and affordable sequencing of large amounts of DNA
(Metzker, 2010). This has expedited sequencing of large gene panels,
all coding genes (the exome) and even whole genomes (Payne et al.,
2018).
Genetic testing in infertility
It is currently thought that at least 15% of all human male infertility
patients can be explained by genetic defects (Krausz and Riera-
Escamilla, 2018). Since the discovery of an extra X chromosome in
Klinefelter patients (47,XXY) (Ferguson-Smith et al., 1957; Jacobs and
Strong, 1959), more than 3500 papers have been published on the
genetics of male infertility, implicating various common genetic origins
as well as hundreds of other genes in male infertility. Despite these
large numbers, genetic diagnostic testing is usually confined to karyo-
typing, azoospermia factor (AZF) deletion screening and cystic fibrosis
transmembrane conductance regulator (CFTR) mutation analysis.
Currently a genetic diagnosis is reached in about 4% of all infertile
males – a number that has not increased since the late 1990s
(Johnson, 1998; Tuttelmann et al., 2018). This is in sharp contrast to
the increase in diagnostic yield seen for other conditions with a strong
genetic component, driven largely by the widespread application of
genomic microarray analysis and NGS (Rehm, 2017; Tuttelmann et al.,
2018). Without a genetic diagnosis it is difficult for a clinician to coun-
sel couples with questions about the causes of their infertility, possible
co-morbidities, the potential success of ART and the reproductive
health of their offspring.
Clinical validity assessment of gene–disease
relationships
With the introduction of and advances in genomics, the number of
genes associated with male infertility has expanded in recent years.
However, the amount of genes confidently linked to disease is still very
limited in comparison to developments in other genetic diseases such
as intellectual disability (Vissers et al., 2016; Tuttelmann et al., 2018).
This is caused in part by a lack of solid evidence linking variation in indi-
vidual genes to human male infertility. The notion of sub-optimal qual-
ity of evidence in male infertility research is not limited to genetic
studies but is considered a general concern in the field of reproductive
biology (Evers, 2013; Barratt, 2016; Glujovsky et al., 2016).
In order to robustly link gene dysfunction to disease, one needs to con-
sider multiple levels of evidence. This is especially important since insuffi-
cient, inconclusive and low-quality evidence may result in incorrect and
misleading conclusions about gene–disease relationships. Moreover, if this
wrongful gene–disease relation is not identified and corrected, it may lead
to inappropriate diagnoses and even mismanagement and counseling of
the infertile couples involved. Furthermore, these incorrectly character-
ized genes may complicate follow-up research by contaminating candidate
disease gene lists and pathway analyses.
Recently, the Clinical Genome Resource (ClinGen) has developed
an extensive framework to assess the clinical validity of a gene–disease
relationship (Strande et al., 2017). However, the overall number of val-
idated disease genes is currently very limited (n = 490) and does not
contain any genes involved in male infertility. Another more simplified
and pragmatic version of this framework was recently published to
more easily assess the clinical validity of gene–disease relationships
(Smith et al., 2017). In the present study, we applied the gene–disease
scoring system of Smith et al. (2017) to curate all available information
on the genetics of human male infertility from 1958 up to December
2018. This analysis allowed us to objectively classify the evidence for
the involvement of genes in male infertility as non-existing, limited,
moderate, strong or definitive. The results from this work may be use-
ful in both research and diagnostics, for example for developing diag-
nostic gene panels and hopefully help to strengthen genetic research in
male infertility.
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Materials andMethods
Search strategy and study selection
Two independent reviewers conducted a literature search in Pubmed
according to the PRISMA guidelines for English articles in peer-reviewed
journals. The search was performed on several occasions with the last
search taking place on 6 December 2018 without further restrictions on
publication date. The search query and screening strategy aimed to collect
all records of genetics research in defective male reproductive develop-
ment and function (Supplementary Table SI). Doubts about inclusion of
any publications were resolved by discussion and consensus between all
authors.
Data extraction and assessment of clinical
validity
From eligible papers presenting original data, we extracted the gene
names, patient phenotypes, inheritance pattern, method of discovery and
whether or not single nucleotide or copy number variants (CNV) were
identified in the genes mentioned in infertile men. After extraction of the
gene names from all records, we employed a recently published gene–dis-
ease scoring system to establish the strength of evidence for the relation-
ship between a gene and male infertility (Smith et al., 2017). A detailed
description of the evidence assessment and an assessment template are
described in Supplementary Tables SII and SIII. Similar to the publication
selection process, disagreements and debatable cases were resolved by
consensus between all authors. In order to prevent bias in gene–disease
evaluation, a second and a third reviewer independently reviewed and
verified a random selection of 12 and 16 gene–disease relationships,
respectively.
Overview of biological knowledge
From all genes with at least limited evidence, we also extracted the
reported or expected results of semen analysis (if available), whether the
patients described are sporadic or familial cases, and whether the type of
infertility was isolated, a reproductive organ syndrome, endocrine disorder
or part of another syndrome. All genes with at least limited evidence were
plotted according to their biological function.
Results
Search strategy and study selection
With our search strategy, we aimed to identify all publications covering
the genetics of male infertility, including those underlying syndromes
affecting the endocrine system, disorders of sex development and
genitourinary anomalies. Our search yielded a grand total of 23 526
publications that date from 1958 to 2018 (Fig. 1). Based on title and
abstract, 18 429 studies were excluded because the publication was
not in written English or the study topic did not match our inclusion
criteria (Supplementary Table SI). Although severe syndromes includ-
ing male infertility phenotypes were excluded because affected
patients are unlikely to seek help to reproduce because of severe
physical or intellectual disabilities, we included milder syndromes and
syndromes affecting the reproductive organs only. A total of 5097 pub-
lications were left. Since the scope of our systematic review is mono-
genic male infertility, we then excluded papers that described genetic
association or risk factors (n = 687), AZF deletions (n = 473), CNVs
affecting multiple genes (n = 30) or chromosomal anomalies (n =
1187). In addition, we excluded 869 publications that, based on full-
text analysis, were not covering the topic of the genetics of male infer-
tility and we excluded 42 papers for which the full text was unavailable.
We then screened the reference lists from included reviews (n = 587)
and were able to add another 115 publications that were not identified
by our search strategy. In total, our search yielded 1337 publications
that met our inclusion criteria (Fig. 1).
The systematic literature search revealed a total of 150–200 publica-
tions per year in the past 10 years and showed that the majority of
publications from the last few years report on monogenic causes of
male infertility (46% in 2017), followed by genetic association or risk
factor analysis (28% in 2017) (Figs 2A and B). Furthermore, the abso-
lute number of karyotype studies has been relatively stable over the
past 20 years at ~30 publications per year.
Data extraction and evaluation of evidence
From the 1337 included publications, we extracted 487 unique Human
Genome Organization (HUGO) approved gene names and 521 gene–
disease relationships (Fig. 1). The number of gene–disease relation-
ships is higher than the number of genes because several genes were
described in multiple male infertility phenotypes. A further look into
the discovery method showed that DNA sequencing has been the
most commonly used technique for novel gene discovery and replica-
tion studies (84% of all publications). At the moment, a shift from
Sanger sequencing to NGS methods is taking place (Fig. 2C).
We then assessed the clinical validity of each gene–disease relation-
ship by using the simplified scoring system designed to establish the
strength of a relationship between a single gene and a Mendelian dis-
ease (Smith et al., 2017) (Supplementary Tables SII and SIII).
After excluding genes that did not contain any potentially pathogenic
variant or were unable to be classified, a total of 345 gene–disease
relationships were curated and classified into the following categories:
definitive (n = 38), strong (n = 22), moderate (n = 32), limited (n =
93) and no evidence (n = 160) (Supplementary Tables SIV and SV).
We identified a total of 78 genes that can at least be moderately linked
to a total of 92 male infertility or abnormal genitourinary development
phenotypes showing autosomal recessive (n = 48), autosomal domin-
ant (n = 31), X-linked (n = 11) and Y-linked (n = 2) inheritance pat-
terns. Patients were found to be sporadic (n = 18), in families (n = 14)
or in both (n = 60) and led to isolated infertility (n = 24), a reproduct-
ive organ or endocrine syndrome (n = 55) or a syndromic form of
infertility (n = 13) (Table I; Supplementary Table SIV). In 176 cases, we
could not evaluate the gene–disease relationship because either the
inheritance pattern remains unclear or suggests polygenic inheritance,
the technical quality of the identification method was too poor or the
exact variant information could not be retrieved (Supplementary
Table SVI).
The results show that the total number of confidently linked
genes is growing steadily at about three genes per year. The
increase in NGS methods being used has caused an exponential
growth in novel candidate genes. However, the vast majority of
these are currently classified as ‘Limited evidence’. In the past 5
years, 84 new disease genes have been described of which only
27% (n = 23) have now been at least moderately linked to male
infertility leaving 73% (n = 61) with a current classification of
‘Limited evidence’ (Fig. 2D).
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Overview of human genes involved in human
male infertility
Taking into account that normal functioning of the male reproductive sys-
tem is biologically mostly dictated by the hypothalamic–pituitary–gonadal
axis, the origins of male infertility can be divided in three major groups:
pre-testicular, testicular and post-testicular. We grouped all genes with at
least limited evidence for an involvement in human male infertility into
these three groups based on their reported biological function (Fig. 3) to
assess whether the curated genes play a role in these biological processes.
Our results show that pre-testicular forms of infertility are mostly
syndromic and caused by endocrine abnormalities, characterized by
low levels of sex steroids and abnormal gonadotrophin levels. Post-
testicular causes include ejaculatory disorders or obstructions, which
impair the transport of spermatozoa from the testis. These obstruc-
tions can be caused by a congenital unilateral or bilateral absence of
the vas deferens.
Despite the fact that monomorphic forms of teratozoospermia are
extremely rare, half of all genes known to cause isolated testicular
forms of infertility are involved in teratozoospermia (n = 10, 50% of all
20). The number of genes confidently linked to the more common
phenotypes oligozoospermia or azoospermia when mutated remains
limited (n = 10, 50% of all 20).
Figure 1 PRISMA flow chart showing our search and screening strategy to identify publications and genes eligible for clinical valid-
ity assessment in male infertility. GD, gene–disease relationships; AR, autosomal recessive; AD, autosomal dominant; XL, X-linked; YL, Y-linked.
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Figure 2 Genetic studies in male infertility between 1958 and 2018. (A) Graphical overview of genetic studies in male infertility. (B) Graphical representation of type of genetic research in
male infertility. (C) The use of Sanger sequencing and next-generation sequencing for the discovery of genes in male infertility. (D) Increase of genes linked to human male infertility. AZF, azoospermia
factor; CNV, copy number variants.
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Discussion
This standardized clinical validity assessment focused on the genetic
causes of infertility and provides a systematic and comprehensive over-
view of all genes implicated as a monogenic cause of male infertility.
Our study aimed to provide an overview of all currently available evi-
dence and gene–disease relationships, as well as formulate a set of
recommendations for future studies involving the genetics of male
infertility.
Clinical validity of gene–disease relationships
in male infertility
In our literature search, we used a simplified version of the extensive
framework used by ClinGen to curate gene–disease relationships and
results in similar evidence categories. The method was previously
described and proved to be reliable, reproducible and similar to the
conclusions of the ClinGen method, which makes the method suitable
for robust and rapid evaluation of genes in both research and diagnos-
tic sequencing settings (Smith et al., 2017). In general, the results of
our clinical validity assessment demonstrate that the quality of evi-
dence for gene–disease relationships as well as the reporting of the
results varies greatly in the field of male infertility.
The results of this clinical validity assessment are not static and as
knowledge increases over time the outcome may be subjected to
changes over time. Hence, we expect that a large number of the genes
that are currently classified as ‘Limited’, ‘No evidence’ or ‘Unable to
classify’ may still play an important role in male infertility and should
therefore not be omitted from future genetic studies.
Evidence from animal models was often strong and genetic studies
clearly benefit from a wealth of studies describing hundreds of well-
characterized male infertility mouse models (de Boer et al., 2015;
Kherraf et al., 2018). However, caution is urged in drawing conclusions
about gene function and inheritance mode based on mouse models
only. The mouse and human reproductive system are not identical and
genes may have (slightly) different functions or transmit disease
through different modes of inheritance (Lieschke and Currie, 2007).
For this reason, we included statistical evidence from large human
datasets to supplement the evidence from animal models (Lek et al.,
2016; Quinodoz et al., 2017). In case the evidence for inheritance pat-
tern was clearly contradictory between mice and human, we did not
evaluate the gene–disease relationship (n = 92).
The number of candidate gene–disease relationships is growing
exponentially as a result of the availability of NGS methods and 2018
has already yielded more novel gene–disease relationships than 2015,
2016 and 2017 combined (Fig. 2D). However, the number of confi-
dently linked gene–disease relationships is not growing at the same
pace. The major reason for this is that most genes have only been
found mutated in single patients and functional evidence is lacking. We
expect the number of genes confidently linked to azoospermia to
grow in the coming years by large-scale data sharing, especially since
this is a common form of infertility and genetic components are very
likely to play an important role in its etiology (Krausz and Riera-
Escamilla, 2018).
Importance of re-evaluation of evidence
The recent availability of large genetic population reference databases
facilitates re-evaluation of reported disease-associated variants and
allows for determining whether the population frequency of the variant
is in line with a reported link to a disorder associated with reduced fit-
ness such as male infertility. Previous reports have shown that healthy
participants on average have ~54 exonic variants that were previously
reported to be pathogenic, but based on their allele frequency were
likely to be misclassified (Lek et al., 2016).
The systematic re-classification of reported genetic sequencing var-
iants in male infertility using this information resulted in some interest-
ing observations. For example, protein interacting with PRKCA 1
(PICK1) is regularly mentioned as a gene that causes globozoospermia
in human patients (De Braekeleer et al., 2015; Ray et al., 2017; Krausz
and Riera-Escamilla, 2018). However, only one patient with one
homozygous variant has ever been described in an initial report of a
Chinese globozoospermia patient and no new patients have been pub-
lished since (Liu et al., 2010). With the current gnomAD database
available, we now know that 1.74% of the East Asian population
carries the variant (http://gnomad.broadinstitute.org/variant/22-
.............................................................................................................................................................................................
Table I Numbers of genes that are at least moderately linked to male infertility or abnormal genitourinary development
phenotypes.
Description AR AD XL YL Total
Type of infertility
Isolated infertility 16 4 4 0 24
Syndromic infertility 9 3 1 0 13
Endocrine disorder/Reproductive system syndrome 23 24 6 2 55
Testicular phenotype
Sertoli cell-only syndrome 2 0 0 0 2
Pre-meiotic arrest 0 1 0 0 1
Meiotic arrest 2 3 1 0 6
Spermiogenesis defect 16 1 1 0 18
Unknown stage or multiple stages affected 3 3 1 0 7
AR, autosomal recessive; AD, autosomal dominant; XL, X-linked; YL, Y-linked.
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Figure 3 Biological overview of the genetics of male infertility. The color of each gene indicates the amount of evidence: Brown: Definitive; Red: Strong; Orange: Moderate. GnRHR:
GnRH receptor, LHCGR: LHCG receptor. A list of gene names and definitions is available in Supplementary Table SIX.
938
O
ud
etal.
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
rep/article-abstract/34/5/932/5377831 by R
adboud U
niversity user on 29 April 2020
38471068-G-A). Globozoospermia is an extremely rare type of male
infertility and the expected allele frequency of a globozoospermia-
causing variant is at least 60-fold lower than the observed allele fre-
quency of this variant. It is therefore highly unlikely that this particular
variant is causing globozoospermia in this patient, based on the allele
frequency.
Despite the gene–disease relation being based on the wrong data,
PICK1 deficiency has been shown to result in disruption of acrosome
formation in mice and PICK1 is expressed in human testis (Xiao et al.,
2009). Hence, based on these observations the gene remains an import-
ant candidate gene for human male infertility. Similar discrepancies in
originally published allele frequencies and currently available allele fre-
quencies were found in several other genes including NLR family pyrin
domain containing 14 (NLRP14) (http://gnomad.broadinstitute.org/
variant/11-7060977-A-T) (Westerveld et al., 2006), septin 12 (SEPT12)
(http://gnomad.broadinstitute.org/variant/16-4833970-C-T) (Lin et al.,
2012) and Rhox homeobox family member 1 (RHOXF1) (http://
gnomad.broadinstitute.org/variant/X-119243190-C-T) (Borgmann et al.,
2016).
Next to the availability of genetic population reference databases,
recently a number of detailed human testis transcriptome studies were
published (Jan et al., 2017; Li et al., 2017; Guo et al., 2018; Hermann
et al., 2018). These studies are of tremendous value to better under-
stand the role of genes in spermatogenesis and help to better classify
the evidence for male infertility gene–disease relationships.
Recommendations for genetic testing in
male infertility
During our study, we noted that international guidelines for nomen-
clature and interpretation of sequencing variants were often not fol-
lowed even long after the introduction and worldwide acceptation of
these guidelines (Richards et al., 2015; den Dunnen et al., 2016). We
identified several errors in nomenclature of sequencing variants and
in some cases the variants were not named in a meaningful and
unequivocal manner rendering them unusable for assessment.
Furthermore, many publications did not mention the expected or pro-
ven inheritance pattern or reached doubtful conclusions about the
mode of inheritance.
In order to ensure efficient sharing and downstream use of newly
identified sequencing variants and genes, it is crucial to report variants
in an unambiguous and standardized way. In adherence to the standard
American College of Medical Genetics guidelines, we have made a list
of recommendations for future reporting of novel male infertility var-
iants (Supplementary Table SVII). Furthermore, our literature study
shows that the quality of evidence of a gene–disease relationship varies
greatly. We recommend the use of public and local genomic reference
databases, and statistical and functional experiments to build evidence
for causality (Supplementary Table SVIII).
The genetics of humanmale infertility:
overview and future perspectives
Our work shows that the field of genetics of male infertility is rapidly
expanding due to the introduction of NGS methods (Fig. 2). However,
currently, of all 521 gene–disease relationships described, only 18%
(n = 92 gene–disease relationships involving 78 genes) have been at
least moderately linked to the disease and an additional 18% (n = 93
gene–disease relationships involving 86 genes) are candidate gene–
disease relationships with only limited evidence for involvement of
the gene in a male infertility phenotype (Supplementary Table SIV;
Fig. 3). Caution is warranted when using genes with limited or no evi-
dence for diagnostic screening.
Similar to other fields in medical genetics, the field of genetics in
male infertility has largely focused on inherited variation. Our ana-
lysis indicates that 52% of all gene–disease relationships with at
least moderate evidence for an involvement in male infertility show
an autosomal recessive inheritance pattern (n = 48 of 92 gene–dis-
ease relationships involving 45 genes) (Table I). Importantly, many
of these genes have been identified in consanguineous families and
are unlikely to play an important role in infertility in the outbred
population. Secondly, many of these genes are associated with very
specific and rare sperm defects. It is therefore unlikely that these
genes will play a major role in the more common quantitative sperm
defects (azoospermia and oligozoospermia) encountered in out-
bred populations. In contrast, our analysis revealed that only 34%
of all gene–disease relationships (n = 31 of 92, involving 24 genes)
with at least moderate evidence for causing male infertility has an
autosomal dominant inheritance pattern (Table I), most of which
are syndromic presentations.
It may perhaps not be surprising that there is only a limited number
of autosomal dominant genes described for male infertility, as patho-
genic variation in these genes can only be passed through the maternal
line. Importantly, however, studies in intellectual disability and devel-
opmental delay have recently pointed to an important role for de novo
germline mutations resulting in autosomal dominant disease (Vissers
et al., 2016). The de novo mutation hypothesis for male infertility is fur-
ther underscored by the fact that de novo chromosomal and structural
variations are well-known causes of male infertility: Klinefelter syn-
drome and AZF deletions almost exclusively occur de novo (Lanfranco
et al., 2004; Colaco and Modi, 2018). The role of de novo point muta-
tions, however, remains unexplored in male infertility so far. At the
moment, only three autosomal dominant genes are moderately linked
to isolated male infertility: doublesex and mab-3 related transcription
factor 1 (DMRT1), kelch like family member 10 (KLHL10) and synapto-
nemal complex protein 3 (SYCP3). Unfortunately, parental samples
were not studied for any of these genes to find out whether the variant
was paternally or maternally inherited or occurred de novo.
Genetic testing in diagnostic settings
The recommendations for genetic testing during the diagnostic work-
up of male infertility patients have only minimally changed over the last
20 years and most of these recommendations still focus on the well-
known and common causes of male infertility that were already known
in the 1990s (Barratt et al., 2017; Jungwirth et al., 2018). For cost-
efficiency, there are guidelines to help stratify patient groups to receive
pre-conceptive genetic tests such as karyotype analysis, AZF deletion
tests or a screening for pathogenic variants in a single gene involved in
a specific phenotype such as Kallmann syndrome. However, after
stratification, in ~40% of all male infertility patients no genetic cause is
found with the above mentioned tests (Krausz and Riera-Escamilla,
2018) and this strongly suggests that much more genetic research is
required and at the same time the use of other diagnostic assays
should be considered.
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Testing all patients for all genetic anomalies was very costly for a
long time. However, in light of the recent developments of novel
sequencing technologies, it is now possible to consolidate one or mul-
tiple tests in a single NGS assay, which will help to cut the costs. The
first examples of NGS-based screening methods have been described
for male infertility (Oud et al., 2017; Fakhro et al., 2018; Patel et al.,
2018). The European Society of Human Genetics (ESHG) and ESHRE
have recently made a recommendation for developing and introducing
new tests, specifically for extended carrier screening (Harper et al.,
2018). The identification of novel disease genes allows for the selec-
tion of genes for male infertility gene panels. For diagnostic purposes,
gene panels should contain genes with a minimal level of evidence of
involvement with disease. We recommend including genes with an evi-
dence classification of at least ‘Moderate’ for the composition of diag-
nostic gene panels. While it is difficult to predict at this moment how
much the diagnostic yield of genetic testing will increase for the differ-
ent subtypes of male infertility, it is realistic to expect the overall yield
to go from the current 4% (Tuttelmann et al., 2018) to more than 10%
in the coming decade.
Conclusion
In this clinical validity assessment, we evaluated a total of 521 gene–
disease relationships involving 487 genes with reported monogenic
association to male infertility and identified 92 gene–disease relation-
ships with at least moderate evidence for a role in male infertility. Our
results as well as our objective approach and recommendations may
aid the robust and rapid identification and incorporation of novel genes
in male infertility diagnostics.
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